Top Story Today
Generic Drugmakers Just Got Their Biggest Legal Win in Years
The Supreme Court unanimously sided with Hikma over Amarin, ruling that generic companies can't be sued for induced patent infringement simply because they followed the FDA's skinny-label rules. The case centered on Hikma's generic version of Vascepa, a cardiovascular drug that pulled in roughly $614 million at peak revenue. Brand companies had argued that calling a product a "generic version" of a brand drug was enough to encourage off-label prescribing. The Court disagreed, demanding concrete proof of active promotion of the patented use. Generic companies that had been scared away from skinny-label strategies now have a clear green light.
Why it matters: This ruling reshapes the power dynamic between brand and generic companies. Expect more aggressive generic launches for blockbuster drugs with split patent timelines, lower settlement payouts, and faster price competition across multi-indication therapies.
Read more →Regulatory & Policy
The FDA Wants to Watch Clinical Trials in Real Time. AstraZeneca and Amgen Are First Up.
For the first time ever, the FDA is receiving live clinical trial data instead of waiting months for bundled reports. AstraZeneca's TRAVERSE cancer trial is already streaming safety signals through a cloud platform called Paradigm Health, with Amgen's STREAM-SCLC trial close behind. The agency also issued a request for information on using AI to redesign trial infrastructure, with a broader pilot launching by August.
Read more →A Bipartisan Bill Could Screen Every U.S.-China Biotech Deal
The Biotech Investment National Security Act (BINSA) would subject licensing deals, joint ventures, and IP transfers involving Chinese partners to Treasury Department review. That includes in-licensing from Chinese biotechs, which is how many small U.S. companies fund their pipelines. Average upfront payments in China-linked deals have doubled to $77.7 million in 2026, making the stakes enormous for the companies caught in the middle.
Read more →Clinical & Pipeline
27 Deaths vs. 9: Zynlonta's Phase 3 Data Put the ADC Hype Cycle on Notice
ADC Therapeutics' lymphoma drug hit its efficacy target in the LOTIS-5 trial but reported three times more patient deaths than the control arm (13.2% vs. 4.6%), with no overall survival benefit. A separate trial was already halted after seven fatal respiratory events. The results inject a sobering counter-narrative into oncology's hottest drug class.
Read more →Thyroid Hormones for Depression? Autobahn's Phase 2 Data Turned Heads.
Autobahn Therapeutics reported a 16.8-point drop on the HAMD-17 depression scale in a Phase 2 trial of elunetirom for bipolar depression; a 3-point change is considered meaningful. Three-quarters of patients responded, half hit remission, and brain imaging showed improved neural connectivity. The catch: only 21 patients, no placebo arm. A Phase 3 is next.
Read more →Deals & Financings
Parabilis Files for a $413M IPO, Testing Whether Biotech's Drought Is Over
Led by former J&J R&D chief Mathai Mammen, Parabilis is attempting one of 2026's largest biotech IPOs after only about 8 priced in all of 2025. Its lead drug showed a 74% objective response rate across more than 150 patients in desmoid tumors with a clean safety profile, and Regeneron is buying $75 million of stock alongside the offering. If the deal prices well, expect a wave of S-1 filings to follow.
Read more →Axsome Blocks Generics From Its Sleep Drug Until 2040
Axsome settled all U.S. patent litigation around narcolepsy drug Sunosi, locking out five generic challengers until at least March 2040. The drug pulled in $124.8 million in 2025 (up 32% year over year) with significant growth potential ahead. For a mid-cap company, that's near-biologic-level patent protection built entirely through legal strategy.
Read more →Rallybio Hands 97% of Itself to a Private Oncology Startup
Rallybio, once a sub-dollar stock, is merging with private oncology company Avenzo Therapeutics in a reverse-merger deal backed by $215 million from Blackstone, T. Rowe Price, and others. Avenzo brings four clinical-stage cancer programs and founders who previously sold Turning Point Therapeutics to BMS for $4.1 billion. Legacy Rallybio shareholders keep just 2.8%.
Read more →RA Capital Built a Turnkey Platform for Running Trials in China
RA Capital's new Swiftbridge platform packages China's clinical trial infrastructure (50-60% cheaper, 60-70% faster) for its 100-plus portfolio companies. RA Capital, a major shareholder in Metsera (sold to Pfizer for $10 billion), is now offering this clinical infrastructure broadly. It's a bold bet on U.S.-China cooperation at the exact moment Washington is trying to restrict it.
Read more →